U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT06825156) titled 'Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 Inhibitors' on Feb. 08.
Brief Summary: To investigate the potential of preoperative initiation (3 days) and perioperative continuation (until day 2 after surgery) of empagliflozin(sodium glucose co transporter 2 inhibitor(SGLT-2i)) 10 mg daily to reduce the acute kidney injury marker neutrophil gelatinase-associated lipocalin (NGAL) measured in serum and urine on day 2 postoperatively in patients undergoing cardiopulmonary bypass surgery by comparing a study medication group to a control group in an open-label set-up.
Study Start Date: March 03, 2022
Study Ty...